http://www.alliedminds.com/

"Allied Minds is an innovation company that forms, funds, manages and builds startups based on early-stage technology originating from U.S. universities and federally funded research institutions. We created a new business model for overcoming early-stage development gap between basic research and commercial development. Our investors are aligned with our vision that cutting-edge invention is an attractive, yet under-developed, asset class. We review numerous ideas but only select opportunities with potential to deliver outsized returns. We create subsidiaries led by seasoned management who know how to turn academic breakthroughs into commercial products and then take them to market. We provide our subsidiaries with capital resources, from seed to self-sustainment. Our aim is to promote growth, generate jobs, foster innovation and create societal benefit."

StockMarketWire.com
Allied Minds posts a pre-tax loss of $52.2m for the six months to the end of June - up froma a restated $39.8m last time. Revenues totalled $1.3 - down from $1.5m a year ago.

Operating losses rose to $51.3m from $39.6m.

Chief executive Chris Silva said, "We continue to deliver on our strategy and our commitments to shareholders. Significant capital was invested into new and existing subsidiary businesses during the reporting period, with an increasing proportion of this funding now being derived from third party investors. This is testimony that the commercial value of our most promising subsidiary companies is now being recognised within the sectors they operate, a trend which is also helping us build yet further partnerships with world class corporations. We continue to add to our portfolio and several of our most promising companies are making strong strides towards commercialisation. This progress gives the Board every confidence for the future of the Group."

StockMarketWire.com
Allied Minds' subsidiary Precision Biopsy has raised an additional $5.0 million in new equity from the sale of additional Series A Preferred shares to investor Woodford Investment Management, as the company continues its global commercialization strategy for its ClariCore Biopsy System, a device platform designed to provide accurate, real-time classification of prostate tissue during biopsy procedures.

The funds will also be used to continue the development of the company's Focal Therapy programme, which seeks to provide targeted, localised therapy to the prostate gland by using the same optical tissue-targeting technology found in the ClariCore system.

"We are delighted to receive the additional support from our leading institutional investor as we prepare to bring our ClariCore Biopsy System to market," said Amir Tehrani, chief executive officer of Precision Biopsy. "We believe that the ClariCore system will help to improve the diagnostic process for millions of patients who undergo biopsy procedures each year to monitor for prostate cancer, the second-most deadly cancer in men after lung cancer."

StockMarketWire.com
Allied Minds has announced the formation of a new subsidiary, Vatic Materials, which has entered into an exclusive option to license certain proprietary technology from The Pennsylvania State University (Penn State).

Vatic Materials plans to focus on developing materials and fabrication processes for advanced transparent conducting thin films that will enable conductive surfaces that are potentially thinner and more cost effective than current approaches.

Transparent conducting thin films are ubiquitous in modern electronics, enabling high performance touchscreens, lighting, photovoltaics, and more.

The proprietary technology, developed in the laboratory of Penn State Materials Science Professor Roman Engel-Herbert, could be used to serve a wide range of applications across several industries, including consumer electronics, photovoltaics, advanced building materials, and solid-state lighting.

StockMarketWire.com
Allied Minds subsidiary HawkEye 360, a developer of a space-based radio frequency (RF) mapping and analytics system, has raised $11.0 million in new equity investments in a Series A preferred financing led by Razor's Edge Ventures, with additional participation by Allied Minds and a defence market leader.

HawkEye 360 also intends to issue up to an additional $2.75 million in Series A preferred shares to new and existing shareholders within 60 days, resulting in a total expected financing of up to $13.75 million.

The funds will be used to complete the development and manufacturing of the HawkEye 360 Pathfinder Cluster of three small satellites, which is scheduled for launch and testing in late 2017, as well as grow the company's engineering and business development teams.

Allied Minds PLC (LON:ALM) was downgraded by research analysts at Jefferies Group LLC to an “underperform” rating in a research report issued to clients and investors on Friday. They currently have a GBX 254 ($3.19) price target on the stock, down from their prior price target of GBX 584 ($7.34). Jefferies Group LLC’s target price suggests a potential downside of 21.02% from the stock’s current price.

StockMarketWire.com
Allied Minds has announced a restructuring and the reallocation of capital and management resources across the portfolio and pipeline which would result in discontinued funding for seven subsidiaries.

The group said a process would be undertaken to seek strategic alternatives for these businesses, which could include sales or transfers of legal entities or assets, or liquidations.

Capital and management resources unlocked from this process would be diverted to other companies and opportunities in the portfolio where there was greatest potential for value creation.

It aid attention would be focused in particular on its more advanced subsidiaries and most promising early stage companies, and on scaling its origination platform to take full advantage of opportunities across its network of research institutions and corporate partnerships.

It said the seven discontinued subsidiaries were: Biotectix; Cephalogics; CryoXtract; Novare Pharmaceuticals; Optio Labs; RF Biocidics; and Tinnitus Treatment Solutions.

It said discontinuation of funding at these subsidiaries would free up approximately $14m of capital spend budgeted for 2017 but so far not undertaken, or approximately $9m net of a restructuring charge currently estimated at $4.7m to be taken in the second quarter.

As at 30 June 2016 the discontinued subsidiaries in aggregate represented $146.6 million of Allied Minds' group subsidiary ownership adjusted value (GSOAV).

The group said it was currently expected that this value would be marked down in its entirety on publication of the full year results, but with some modestly offsetting net positive movements elsewhere in the portfolio.

Allied Minds is a failing company lacking innovation and also funding. Sell. Now 204p

This has gone way below its IPO price in 2014. Now 168p as Invesco has reduced its stake in Allied Minds.

Numis today reaffirms its hold investment rating on Allied Minds PLC (LON:ALM) and set its price target at 165p.

Jefferies International today (03/05/17) reaffirms its hold investment rating on Allied Minds PLC (LON:ALM) and cut its price target to 176p (from 195p).

StockMarketWire.com
Allied Minds portfolio company BridgeSat has completed a $6m series A funding round, including participation from Space Angels, an early stage investment group comprising experts in the Space 2.0 field.

Allied Minds said the fundraise was completed at a pre-money valuation of $15m, up from the previous valuation of $7m.

It said proceeds would be used to accelerate the three core elements of BridgeSat's solution: space terminal (the equipment fixed to customer satellites), ground stations (receiving the data from space) and network (transmitting the data to end customers via cloud based software).

Allied Minds chief executive Jill Smith said: "We are excited by the rapid progress BridgeSat has made in advancing the key elements of its optical downlink network; a technology that has the potential to unlock significant benefits for the large and fast growing LEO data downlink market.

"The participation of Space Angels in this funding round is an important validation for the business, and is consistent with our objective to broaden Allied Minds' funding syndicate and secure investment from strategic and independent financial investors at an earlier stage in our subsidiaries' development.

"The BridgeSat fundraise follows the successful Series A round for HawkEye 360 completed at the end of 2016, and underlines Allied Minds' growing expertise in the satellite and data management verticals."

StockMarketWire.com
Allied Minds portfolio company Signature Medical has completed a $2.5 million series A preferred financing round, including participation by Riot Ventures, an early stage investment fund focused on emerging technology, and Bose Corporation, a global leader in audio innovation.

Signature Medical is developing wearable devices using acoustic signature analysis and artificial intelligence allied to cloud-based technology to evaluate and monitor patients remotely and on a real time basis.

Its lead AcoustiCare device is designed for patients with heart failure and other indications.

Proceeds from the financing will be used to fund product development.

Allied Minds president and chief executive Jill Smith said: "We are pleased to have secured participation by Riot and Bose in the funding for this high potential company, consistent with our desire to attract investment and validation from strategic and financial partners earlier in the investment life cycle where we see benefits from doing so, as we have done recently with our HawkEye 360 and BridgeSat series A rounds."

StockMarketWire.com
Allied Minds invested $22.4 million into its portfolio companies in the six months ended 30 June.

Net cash and investments at 30 June totalled $177.0m (FY16: $226.1m), of which $113.3m was held at parent level.

Other financial highlights:
- Revenue: $2.0 million (HY16: $1.3m)

- Loss for the period: $58.2 million (HY16: $52.2m), of which $44.6 million attributable to Allied Minds (HY16: $41.2m)

- The directors estimate that as of 30 June the group subsidiary ownership adjusted value was $415.8 million ($416.2m as last reported)

On 5 April Allied Minds announced a restructuring, ceasing operations at 7 subsidiaries: Biotectix; Cephalogics; CryoXtract; ProGDerm (dba Novare Pharmaceuticals); Optio Labs; RF Biocidics; and Soundcure / Tinnitus Treatment Solutions.

The group said the the plan had been substantially completed with two of the companies (Biotectix and RF Biocidics) in final stages of the process. 4

President and chief executive Jill Smith said: "We have set out clear goals for the Group with the aim of sharpening capital allocation discipline, including: transitioning to thematic investing; securing earlier and broader syndication of investment partnerships for our portfolio companies where we see scope to validate and accelerate the path to commercialisation; and strengthening the governance and leadership of our portfolio companies.

"Actions undertaken since April across our investment, syndication and operating activities have been consistent with these objectives.

"We have also set out clear goals (MBOs) for our top six companies and ABLS, based on material and commercially relevant milestones, designed to bring about tangible progress towards commercialisation.

"In the short period of time since April, these subsidiaries have progressed well against their respective MBOs, with further achievements expected for the balance of the year.

"I look forward to building on these initial steps with the team as we continue to focus on our objective to drive shareholder value by realising liquidity events that deliver attractive returns for our investors and stakeholders, and accelerating the growth of our underlying business platform."

Numis today upgrades its investment rating on Allied Minds PLC (LON:ALM) to buy (from hold) and raised its price target to 170p (from 165p).

StockMarketWire.com
Allied Minds subsidiary Spin Transfer Technologies and Tokyo Electron have signed an agreement for a collaborative engineering programme for next-generation SRAM and DRAM-class ST-MRAM devices.

Allied Minds said the combination of STT's ST-MRAM technology and TEL's advanced PVD MRAM deposition tool would allow the companies to quickly develop processes for the highest density and endurance devices.

StockMarketWire.com
SciFluor Life Sciences, a subsidiary of Allied Minds, has announced positive top-line results of a phase 1/2 trial studying the treatment of 'wet' age-related macular degeneration patients with SF0166, the company's lead eye drop drug for back of the eye diseases.

The double masked phase 1/2 study assessed the safety, tolerability and preliminary efficacy of SF0166 in 42 evaluable subjects with neovascular (wet) AMD who were randomised 1:1 to self-administer an eye drop containing either a 2.5% or a 5% solution of SF0166 twice-a-day for 28 days.

It said the primary outcome measure of safety was clearly achieved with no drug-related serious adverse events observed in the study throughout the 28-day course of treatment as well as during the 28-day follow-up period.

Ocular adverse events were recorded in the treated eyes of 5 patients; all events were mild or moderate in severity, with one considered possibly drug-related.

Credit Suisse today reaffirms its neutral investment rating on Allied Minds PLC (LON:ALM) and cut its price target to 110p (from 175p).

2 years ago these were 450p a share now 50p.

bargain.